Results 81 to 90 of about 531,735 (303)

Impact of Initial Treatment Setting on Survival in Relapsed Pediatric and AYA Bone Sarcomas: A Secondary Analysis of a Prospective Clinical Trial

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background Outcomes in relapsed or refractory pediatric and AYA bone sarcomas remain poor, and the impact of early referral to specialized sarcoma centers on survival is unclear. Early centralization of care may improve local and systemic treatment quality, but evidence in this population is limited.
Justyna Antoniuk‐Majchrzak, Katarzyna Bilska, Tomasz Koziński, Jadwiga Węcławek‐Tompol, Dorota Sega‐Pondel, Radosław Chaber, Wanda Badowska, Katarzyna Rosłan, Hanna Koseła‐Paterczyk, Anna Raciborska   +9 more
wiley   +1 more source

The detection of patients at risk of gastrointestinal toxicity during pelvic radiotherapy by electronic nose and FAIMS : a pilot study [PDF]

, 2012
It is well known that the electronic nose can be used to identify differences between human health and disease for a range of disorders. We present a pilot study to investigate if the electronic nose and a newer technology, FAIMS (Field Asymmetric Ion ...
Ouaret, N., Arasaradnam, Ramesh P., Linda Wedlake, Andreyev, J., Jervoise Andreyev, James A. Covington, Chuka U. Nwokolo, Matthew G. Thomas, Covington, James A., Nathalie Ouaret, Thomas, Matthew G., Wedlake, L., Nwokolo, Chuka U., Ramesh P. Arasaradnam, Bardhan, Karna Dev, Karna D. Bardhan   +15 more
core   +1 more source

Lorlatinib‐Containing Therapy for MYCN‐Amplified, ALK‐Mutated Neuroblastoma With Bulky Leptomeningeal Relapse: A Case Report

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Central nervous system (CNS) relapse of neuroblastoma carries a poor prognosis, and craniospinal irradiation (CSI) poses substantial long‐term toxicity in young children. We report a toddler with MYCN‐amplified neuroblastoma harboring somatic ALK R1275Q who developed extensive leptomeningeal relapse with paraplegia.
Jinwoo Kim, Minji Kim, Nani Jung, Sung Eun Kim, Ji Yoon Kim, Mi Ae Chu, Jung Eun Kwon, Yeo Hyang Kim, So Mi Lee, Ki‐Su Park, Jeong Eun Lee, Ye Jee Shim   +11 more
wiley   +1 more source

IMPDH inhibition enhances cytarabine efficacy in SAMHD1‐expressing leukaemia cells via guanine nucleotide depletion

Molecular Oncology, EarlyView.
Cytarabine is a key therapy for acute myeloid leukaemia (AML), but its efficacy is limited by the dNTPase SAMHD1, which hydrolyses its active metabolite. Screening nucleotide biosynthesis inhibitors revealed that IMPDH inhibitors selectively sensitise SAMHD1‐proficient AML cells to cytarabine.
Miriam Yagüe‐Capilla, Christopher Dirks, Caroline Eiden, Sonja K. Fesenmayer, Femke M. Hormann, Yolande Klootsema, Ingrid Lilienthal, Si Min Zhang, Nikolas Herold, Sean G. Rudd   +9 more
wiley   +1 more source

Assessment of Dosimetric Accuracy and Plan Quality in Prostate SBRT Using RapidArc with Analysis of Varian MLC Parameters [PDF]

Iranian Journal of Medical Physics
Introduction: Prostate cancer is a highly prevalent malignancy worldwide. Advances in radiotherapy, particularly SBRT, have enabled ultra-hypofractionated treatments that improve tumor control while reducing treatment time.
Ajithkumar M, Subhankar Show, Aaditya Prakash   +2 more
doaj   +1 more source

Developmental programmes drive cellular plasticity, disease progression and therapy resistance in lung adenocarcinoma

Molecular Oncology, EarlyView.
This study shows that lung adenocarcinomas exploit developmental branching morphogenesis to acquire a therapy resistant basal‐like tumour cell state. This process was found to be regulated by combined TP53 loss‐of‐function and type‐I interferon signalling, identifying a novel axis for biomarker and therapeutic target discovery.
Kamila J Bienkowska, Stephany Gallardo, Nur S. Zainal, Leena Arora, Matthew Ellis, Maria‐Antoinette Lopez, Judith Austine, Sai Pittla, Serena J Chee, Aiman Alzetani, Emily C Shaw, Christian H Ottensmeier, Gareth J Thomas, Christopher J Hanley   +13 more
wiley   +1 more source

Treatment Continuity and Bone Marrow Suppression in Whole-Brain and Whole-Spinal Cord Radiotherapy for Medulloblastoma Patients

Clinical Medicine Insights: Oncology
Background: This study investigated the factors influencing treatment continuity and bone marrow suppression in whole-brain and whole-spinal cord radiotherapy for medulloblastoma, providing a clinical reference for mitigating the impact of hematological ...
Zongtai Li, Zhiyue Lin, Hui Liu, Runnan Xiao, Chuyan Lin, Wenlong Zhu, Jiaxiu Luo, Senku Xu, Feng Chi, Huilang He   +9 more
doaj   +1 more source

Stimulator of interferon genes agonist augmented antitumor immunity of osimertinib in Egfr‐mutated lung cancer

Molecular Oncology, EarlyView.
Combining osimertinib with the STING agonist ADU‐S100 activates innate and adaptive immunity to overcome the non‐inflamed microenvironment of Egfr‐mutant lung cancer. This combination increases NK and CD8+ T‐cell infiltration, associated with activation of the STING‐IRF3 pathway and local immunogenic cell death.
Jun Nishimura, Tadahiro Kuribayashi, Johannes Brägelmann, Sachi Okawa, Masataka Taoka, Shunta Mori, Tomoka Nishimura, Takaaki Tanaka, Go Makimoto, Kiichiro Ninomiya, Kammei Rai, Eiki Ichihara, Ryohei Katayama, Katsuyuki Hotta, Masahiro Tabata, Yosuke Togashi, Yoshinobu Maeda, Martin L. Sos, Katsuyuki Kiura, Kadoaki Ohashi   +19 more
wiley   +1 more source

Coping of cancer patients during and after radiotherapy - a follow-up of 2 years [PDF]

, 2003
Aim: We wanted to understand coping strategies specific to different phases up to two years after radiotherapy, to identify patients who are at higher risk of mood disturbances and to characterise the association between coping strategies and ...
Fahmüller, H., Sehlen, Susanne, Herschbach, P., Aydemir, U., Lenk, M., Dühmke, Eckhart, Hollenhorst, H., Schymura, B., Song, R., Sehlen, S;Song, R;Fahmüller, H;Herschbach, P;Lenk, M;Hollenhorst, H;Schymura, B;Aydemir, U;Duhmke, E, Sehlen, S.;Song, R.;Fahmüller, H.;Herschbach, P.;Lenk, M.;Hollenhorst, H.;Schymura, B.;Aydemir, U.;Dühmke, E.   +10 more
core   +1 more source

Loss of IGF‐1R impairs DNA‐PKcs recruitment to chromatin leading to defective end‐joining

Molecular Oncology, EarlyView.
IGF‐1R promotes radioresistance by facilitating DNA‐PKcs recruitment to chromatin, enabling non‐homologous end‐joining (NHEJ) repair of double‐strand breaks. Inhibition or loss of IGF‐1R disrupts this recruitment to damage sites, driving compensatory reliance on microhomology‐mediated end‐joining (MMEJ) repair.
Matthew O. Ellis, Jack V. Mills, Wojciech Niedzwiedz, Valentine M. Macaulay   +3 more
wiley   +1 more source